Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kobayashi Pharmaceutical Co., Ltd. (4967:JPX), powered by AI.
Kobayashi Pharmaceutical Co., Ltd. is currently trading at ¥5,468. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Kobayashi Pharmaceutical Co., Ltd. on Alpha Lenz.
Kobayashi Pharmaceutical Co., Ltd.'s P/E ratio is 111.2.
“Kobayashi Pharmaceutical Co., Ltd. trades at a P/E of 111.2 (premium valuation) with modest ROE of 1.7%.”
Ask for details →Kobayashi Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, specializing in developing, manufacturing, and selling consumer health products. The company's portfolio includes over-the-counter medications, health supplements, and household products that focus on improving everyday life. Kobayashi is renowned for providing innovative healthcare solutions that cater to both preventive and therapeutic needs. Its offerings are primarily aimed at individuals, aiming to address common health concerns such as allergies, colds, and skincare conditions, while also providing wellness and dietary supplements. With a strong focus on research and development, Kobayashi maintains its competitive edge by frequently releasing new products that meet the evolving demands of the healthcare market. With its headquarters in Japan, the company has successfully expanded its presence internationally, significantly impacting the consumer health sector across Asia, Europe, and North America. In the financial markets, Kobayashi Pharmaceutical Co. stands as a key player, representing the broader consumer health industry and contributing to advancements in public health.
“Kobayashi Pharmaceutical Co., Ltd. trades at a P/E of 111.2 (premium valuation) with modest ROE of 1.7%.”
Ask for details →Kobayashi Pharmaceutical Co., Ltd. (ticker: 4967) is a company listed on JPX in the Consumer Defensive sector (Household & Personal Products). It has approximately 3,615 employees. Market cap is $406.5B.
The current price is 5,468 with a P/E ratio of 111.18x and P/B of 1.93x.
ROE is 1.72% and operating margin is 9.01%. Annual revenue is $165.7B.